New Players in Big Pharma Dealmaking
Executive SummaryIn spite of biotech’s weakness on Wall Street, dealmaking in discovery research has been surprisingly rich in recent months, in part thanks to a group of drug companies new to dealmaking or with revived dealmaking programs. Most partners are not seeking to capitalize on biotech’s weakness. Instead, they aim to fill gaps in their pipelines with novel compounds for a value-sensitive marketplace.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.